جهانی در حال گسترش از مواد روان گردان جدید – بنزودیازپین های طراحی شده (DBZD)

نوع مقاله : مقاله پژوهشی

نویسندگان

1 کارشناس بیوشیمی

2 کارشناس انتظامی

چکیده

  سوء استفاده از مواد روان گردان جدید (NPS) از اواخر دهه 2000 در سرتاسر جهان به طور چشمگیری افزایش یافته است . بین سال های 2009 تا 2017 در مجموع 803 نوع NPS ویژه توسط 111 کشور و حوزه به دفتر مواد مخدر و جرم سازمان ملل گزارش شده است. اگرچه عمومی ترین این ترکیبات کانابینوئید های مصنوعی و مشتقات کاتیون های محرک (به اصطلاح بتا کتوآمفتامین ها) هستند، بنزودیازپین های جدید به تازگی در بازار داروهای تفریحی ظاهر شده اند. سوء استفاده از "بنزودیازپین های طراحی شده" (DBZD) (یک نام مشترک برای کلاس NPS بنزودیازپین ها) در بسیاری از کشورها به یک معضل فزاینده ای تبدیل شده است.
گروه DBZD شامل نامزدهایی از داروهایی هستند که هرگز برای استفاده پزشکی تایید نشده اند.DBZD درواقع ترکیباتی هستند که با دستکاری و اصلاح ساختاری ساده یک دارو و نیز برخی متابولیت های فعال بنزودیازپین هایی سنتز شده اند. این مقاله اعضای گروه DBZD حال حاضر را بررسی می کند، و روند اپیدمیولوژیک و اثرات بالینی مرتبط با مصرف آن ها را شرح می دهد و داده های به دست آمده در خصوص متابولیسم آن ها را مورد بحث قرار می دهد و تاکید ویژه ای به موارد مسمومیت به این ترکیبات دارد.

کلیدواژه‌ها

El Balkhi, S., Chaslot, M., Picard, N., Dulaurent, S., Delage, M., Mathieu, O., Saint-
Marcoux, F., 2017. Characterization and identification of eight designer benzodiazepine
metabolites by incubation with human liver microsomes and analysis by a
triple quadrupole mass spectrometer. Int. J. Legal Med. 131 (4), 979–988. https://
doi.org/10.1007/s00414-017-1541-6.
EMCDDA, 2016. European Drug Report. Trends and Developments. Accessed 29
November 2018. http://www.emcdda.europa.eu/system/files/publications/2637/
TDAT16001ENN.pdf.
EMCDDA, 2018a. Perspective on Drugs. The Misuse of Benzodiazepines Among High-risk
Opioid Users in Europe. Accessed October 9, 2018. http://www.emcdda.europa.eu/
system/files/publications/2733/Misuse%20of%20benzos_POD2015.pdf.
EMCDDA, 2018b. European Drug Report. Trends and Developments, 2018. Accessed
October 9, 2018. http://www.emcdda.europa.eu/system/files/publications/8585/
20181816_TDAT18001ENN_PDF.pdf.
Ghazi, M.A., Mohmand, M., 2017. Co-occurring addition of synthetic benzodiazepine
clonazolam and propylhexedrine presenting as acute brief psychosis. J. Addict. Med.
Ther. Sci. 5 (2), 1037.
Gjerde, H., Christophersen, A.S., Normann, P.T., Mørland, J., 2011. Toxicological investigations
of drivers killed in road traffic accidents in Norway during 2006-2008.
Forensic Sci. Int. 212 (1–3), 102–109. https://doi.org/10.1016/j.forsciint.2011.05.
021.
Griffin 3rd, C.E., Kaye, A.M., Bueno, F.R., Kaye, A.D., 2013. Benzodiazepine pharmacology
and central nervous system-mediated effects. Ochsner J. 13 (2), 214–223.
Gupta, S., Garg, B., 2014. A case of etizolam dependence. Indian J. Pharmacol. 46 (6),
655–656. https://doi.org/10.4103/0253-7613.144943.
Høiseth, G., Tuv, S.S., Karinen, R., 2016. Blood concentrations of new designer benzodiazepines
in forensic cases. Forensic Sci. Int. 268, 35–38. https://doi.org/10.1016/j.
forsciint.2016.09.006.
Huppertz, L.M., Moosmann, B., Auwärter, V., 2018. Flubromazolam - Basic pharmacokinetic
evaluation of a highly potent designer benzodiazepine. Drug Test. Anal. 10
(1), 206–211. https://doi.org/10.1002/dta.2203.
Jones, J.D., Mogali, S., Comer, S.D., 2012. Polydrug abuse: a review of opioid and benzodiazepine
combination use. Drug Alcohol Depend. 125 (1–2), 8–18. https://doi.
org/10.1016/j.drugalcdep. 2012.07.004.
Karinen, R., Tuv, S.S., Rogde, S., Peres, M.D., Johansen, U., Frost, J., Vindenes, V.,
Øiestad, Å.M., 2014. Lethal poisonings with AH-7921 in combination with other
substances. Forensic Sci. Int. 244, e21–24. https://doi.org/10.1016/j.forsciint.2014.
08.013.
Katselou, M., Papoutsis, I., Nikolaou, P., Spiliopoulou, C., Athanaselis, S., 2017.
Metabolites replace the parent drug in the drug arena. The cases of fonazepam and
nifoxipam. Forensic Toxicol. 35 (1), 1–10. https://doi.org/10.1007/s11419-016-
0338-5.
Kerrigan, S., Mellon, M.B., Hinners, P., 2013. Detection of phenazepam in impaired
driving. J. Anal. Toxicol. 37 (8), 605–610. https://doi.org/10.1093/jat/bkt075.
Kintz, P., Richeval, C., Jamey, C., Ameline, A., Allorge, D., Gaulier, J.M., Raul, J.S.,
2017a. Detection of the designer benzodiazepine metizolam in urine and preliminary
data on its metabolism. Drug Test. Anal. 9 (7), 1026–1033. https://doi.org/10.1002/
dta.2099.
Kintz, P., Jamey, C., Ameline, A., Richeval, C., Raul, J.S., 2017b. Characterization of
metizolam, a designer benzodiazepine, in alternative biological specimens. Toxicol.
Anal. Clin. 29, 57–63 https://dx.doi.org/1016/j.toxac.2016.09.04.
Koch, K., Auwärter, V., Hermanns‐Clausen, M., Wilde, M., Neukamm, M.A., 2018. Mixed
intoxication by the synthetic opioid U‐47700 and the benzodiazepine flubromazepam
with lethal outcome: pharmacokinetic data. Drug Test. Anal https://doi.org/
10.1002/dta.2391.
Kriikku, P., Wilhelm, L., Rintatalo, J., Hurme, J., Kramer, J., Ojanperä, I., 2012.
Phenazepam abuse in Finland: findings from apprehended drivers, post-mortem cases
and police confiscations. Forensic Sci. Int. 220 (1–3), 111–117. https://doi.org/10.
1016/j.forsciint.2012.02.006.
Liveri, K., Constantinou, M.A., Afxentiou, M., Kanari, P., 2016. A fatal intoxication related
to MDPV and pentedrone combined with antipsychotic and antidepressant substances
in Cyprus. Forensic Sci. Int. 265, 160–165. https://doi.org/10.1016/j.forsciint.2016.
02.017.
Lomas, E.C., Maskell, P.D., 2015. Phenazepam: more information coming in from the
cold. J. Forensic Leg. Med. 36, 61–62. https://doi.org/10.1016/j.jflm.2015.08.017.
Łukasik-Głębocka, M., Sommerfeld, K., Teżyk, A., Zielińska-Psuja, B., Panieński,
immunochemical
screening assays. Drug Test. Anal. 9 (4), 640–645. https://doi.org/10.
1002/dta.2003.
Pettersson Bergstrand, M., Meyer, M.R., Beck, O., Helander, A., 2018. Human urinary
metabolic patterns of the designer benzodiazepines flubromazolam and pyrazolam
studied by liquid chromatography-high resolution mass spectrometry. Drug Test.
Anal. 10 (3), 496–506. https://doi.org/10.1002/dta.2243.
Pettersson Bergstrand, M., Richter, L.H.J., Maurer, H.H., Wagmann, L., Meyer, M.R.,
2019. In vitro glucuronidation of designer benzodiazepines by human UDP-glucuronyltransferases.
Drug Test. Anal. 11 (1), 45–50. https://doi.org/10.1002/dta.2463.
Pope, J.D., Choy, K.W., Drummer, O.H., Schneider, H.G., 2018. Novel benzodiazepines
(clonazolam and flubromazolam) identified in candy-like pills. J. Appl. Lab. Med. 3
(1), 48–55. https://doi.org/10.1373/jalm.2017.025387.
Shearer, K., Bryce, C., Parsons, M., Torrance, H., 2015. Phenazepam: a review of medicolegal
deaths in South Scotland between 2010 and 2014. Forensic Sci. Int. 254,
197–204. https://doi.org/10.1016/j.forsciint.2015.07.033.
Stephenson, J.B., Golz, D.E., Brasher, M.J., 2013. Phenazepam and its effects on driving.
J. Anal. Toxicol. 37 (1), 25–29. https://doi.org/10.1093/jat/bks080.
Švidrnoch, M., Boráňová, B., Tomková, J., Ondra, P., Maier, V., 2018. Simultaneous determination
of designer benzodiazepines in human serum using non-aqueous capillary
electrophoresis - Tandem mass spectrometry with successive multiple ionic -
Polymer layer coated capillary. Talanta 176, 69–76 https://doi.org/ 10.1016/j.talanta.
2017.08.010.
Tan, K.R., Rudolph, U., Lüscher, C., 2011. Hooked on benzodiazepines: GABAA receptor
subtypes and addiction. Trends Neurosci. 34 (4), 188–197 https://doi.org/ 10.1016/
j.tins.2011.01.004.
Tanaka, N., Kinoshita, H., Nishiguchi, M., Jamal, M., Kumihashi, M., Takahashi, M.,
Nishio, H., Ameno, K., 2011a. An autopsy case of multiple psychotropic drug poisoning.
Soud. Lek. 56 (3), 38–39.
Tanaka, N., Kinoshita, H., Jamal, M., Ohkubo, E., Kumihashi, M., Ameno, K., 2011b. A
case of drowning whilst under the influence of brotizolam, flunitrazepam and
ethanol. Soud. Lek. 56 (1), 5–6.
TripSit FactSheets, http://drugs.tripsit.me. Accessed 11 October 2018.
UNODC, 2017a. Non-medical Use of Benzodiazepines: a Growing Threat to Public
Health? Global Smart Update. pp. 18. https://www.unodc.org/documents/scientific/
Global_SMART_Update_2017_Vol_18.pdf.
UNODC, 2017b. The Challenge of Synthetic Drugs in East and South-East Asia. Trends and
Patterns of Amphetamine-type Stimulants and New Psychoactive Substances.
Accessed 9 October 2018.. https://www.unodc.org/documents/scientific/Trends_
and_Patterns_of_ATS_and_NPS_2017.pdf.
UNODC, 2017c. April 2017 – UNODC: Several Countries Place Benzodiazepine
Derivatives Under National Control. Accessed 9 October 2018.. https://www.unodc.
org/LSS/Announcement/Details/065118d5-b238-48d8-9d7f-b95fb5d11411.
UNODC, 2018. June 2018 – Scotland: Number of Deaths Involving Benzodiazepine-type
NPS Etizolam and Diclazepam Increase Sharply in 2016. Accessed October 9, 2018.
https://www.unodc.org/LSS/Announcement/Details/0ec8745d-da7e-4594-a47fc47005a8ae96.
US Department of Justice Drug Enforcement Administration, 2009. Blotter acid mimic
(actually containing phenazepam) in North Carolina. Microgram Bulletin 42, 94.
Valen, A., Bogstrand, S.T., Vindenes, V., Gjerde, H., 2017. Toxicological findings in suspected
drug-impaired drivers in Norway - Trends during 1990-2015. Forensic Sci. Int.
280, 15–24. https://doi.org/10.1016/j.forsciint.2017.09.010.
Vikingsson, S., Wohlfarth, A., Andersson, M., Gréen, H., Roman, M., Josefsson, M.,
Kugelberg, F.C., Kronstrand, R., 2017. Identifying metabolites of meclonazepam by
high-resolution mass spectrometry using human liver microsomes, hepatocytes, a
mouse model, and authentic urine samples. AAPS J. 19 (3), 736–742. https://doi.
org/10.1208/s12248-016-0040-x.
Wakakura, M., Tsubouchi, T., Inouye, J., 2004. Etizolam and benzodiazepine induced
blepharospasm. J. Neurol. Neurosurg. Psychiatry. 75 (3), 506–507.
WHO, 2015. Phenazepam. Pre-review Report. Agenda Item 5.8. Expert Committee on
Drug Dependence Thirty-seventh Meeting. Geneva, 16-20 November 2015. . http://
www.who.int/medicines/access/controlled-substances/5.8_Phenazepam_PreRev.pdf.
WHO, 2017. ETIZOLAM Critical Review Report. Agenda Item 4.13. Expert Committee on
Drug DependenceThirty-ninth Meeting Geneva, 6-10 November. 2017. http://www.
who.int/medicines/access/controlled-substances/CriticalReview_Etizolam.pdf.
Wohlfarth, A., Vikingsson, S., Roman, M., Andersson, M., Kugelberg, F.C., Green, H.,
Kronstrand, R., 2017. Looking at flubromazolam metabolism from four different
angles: metabolite profiling in human liver microsomes, human hepatocytes, mice
and authentic human urine samples with liquid chromatography high-resolution
 
Abouchedid, R., Gilks, T., Dargan, P.I., Archer, J.R.H., Wood, D.M., 2018. Assessment of
the availability, cost, and motivations for use over time of the new psychoactive
substances – benzodiazepines diclazepam, flubromazepam, and pyrazolam – in the
UK. J. Med. Toxicol. 14 (2), 134–143. https://doi.org/10.1007/s13181-018-0659-3.
Advice Council on Misuse of Drugs, 2017. Circular 008/2017: a Change to the Misuse of
Drugs Act 1971 to Control U-47,700, Twelve Methylphenidate Related Substances
and Sixteen ‘designer’ Benzodiazepines. Accessed 29 November 2018. https://assets.
publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/
file/616781/misuse_of_drugs_act_circular_008_2017.pdf.
Advisory Council on the Misuse of Drugs, 2011. Phenazepam Advice. Available from:
http://www.homeoffice.gov.uk/publications/agencies-public-bodies/acmd1/acmdadvice-
phenazepam?view=Binary. Accessed October 12, 2018.
Ali, A., Jerry, J.M., Khawam, E.A., 2015. Delirium induced by a new synthetic legal intoxicating
drug: phenazepam. Psychosomatics 56 (4), 414–418. https://doi.org/10.
1016/j.psym.2014.05.018.
Ameline, A., Richeval, C., Gaulier, J.-M., Raul, J.-S., Kintz, P., 2018. Detection of the
designer benzodiazepine flunitrazolam in urine and preliminary data on its metabolism.
Drug Test. Anal. https://doi.org/10.1002/dta.2480.
Anderson, M., Kjeligren, A., 2017. The slippery slope of flubromazolam: experiences of a
novel psychoactive benzodiazepine as discussed on a Swedish online forum. Nordic
Studies Alc. Drugs 34 (3), 217–229. https://doi.org/10.1177/1455072517706304.
Arens, A.M., van Wijk, X.M., Vo, K.T., Lynch, K.L., Wu, A.H., Smollin, C.G., 2016. Adverse
effects from counterfeit alprazolam tablets. JAMA Intern. Med. 176 (10), 1554–1555.
https://doi.org/10.1001/jamainternmed.2016.4306.
Bäckberg, M., Pettersson Bergstrand, M., Beck, O., Helander, A., 2018. Occurrence and
time course of NPS benzodiazepines in Sweden - results from intoxication cases in the
STRIDA project. Clin. Toxicol. Phila. (Phila) https://doi.org/ 10.1080/
15563650.2018.1506130.
Bailey, K., Richards-Waugh, L., Clay, D., Gebhardt, M., Mahmoud, H., Kraner, J.C., 2010.
Fatality involving the ingestion of phenazepam and poppy seed tea. J. Anal. Toxicol.
34 (8), 527–532.
Benerjee, D., 2018. Etizolam withdrawal catatonia: the first case report. Asian J.
Psychiatr. 37, 32–33. https://doi.org/10.1016/j.ajp.2018.07.019.
Benesch, M.G.K., Iqbal, S.J., 2018. Novel psychoactive substances: overdose of 3-fluorophenmetrazine
(3-FPM) and etizolam in a 33-year-old man. BMJ Case Rep.
2018https://doi.org/10.1136/bcr-2018-224995. pii: bcr-2018-224995.
Bertol, E., Di Milia, M.G., Fioravanti, A., Mari, F., Palumbo, D., Pascali, J.P., Vaiano, F.,
2018. Proactive drugs in DFSA cases: toxicological findings in an eight-years study.
Forensic Sci. Int. 291, 207–215. https://doi.org/10.1016/j.forsciint.2018.08.032.
Carpenter, J.E., Murray, B.P., Dunkley, C., Kazzi, Z.N., Gittinger, M.H., 2018. Designer
benzodiazepines: a report of exposures recorded in the National Poison Data System,
2014–2017. Clin. Toxicol. Phila. (Phila). https://doi.org/10.1080/15563650.2018.
1510502.
Corkery, J.M., Schifano, F., Ghodse, A.H., 2012. Phenazepam abuse in the UK: an
emerging problem causing serious adverse health problems, including death. Hum.
Psychopharmacol. 27 (3), 254–261. https://doi.org/10.1002/hup.2222.
Couch, R.A., Madhavaram, H., 2012. Phenazepam and cannabinomimetics sold as herbal
highs in New Zealand. Drug Test. Anal. 4 (6), 409–414.
Crichton, M.L., Shenton, C.F., Drummond, G., Beer, L.J., Seetohul, L.N., Maskell, P.D.,
2015. Analysis of phenazepam and 3-hydroxyphenazepam in post-mortem fluids and
tissues. Drug Test. Anal. 7 (10), 926–936. https://doi.org/10.1002/dta.1790.
Dargan, P.I., Davies, S., Puchnarewicz, M., Johnston, A., Wood, D.M., 2013. First reported
case in the UK of acute prolonged neuropsychiatric toxicity associated with analytically
confirmed recreational use of phenazepam. Eur. J. Clin. Pharmacol. 69 (3),
361–363. https://doi.org/10.1007/s00228-012-1361-z.
Domingo, O., Roider, G., Stöver, A., Graw, M., Musshoff, F., Sachs, H., Bicker, W., 2017.
Mitragynine concentrations in two fatalities. Forensic Sci. Int. 271, e1–e7. https://
doi.org/10.1016/j.forsciint. 2016.12.020.
Drummer, O.H., Kourtis, I., Beyer, J., Tayler, P., Boorman, M., Gerostamoulos, D., 2012.
The prevalence of drugs in injured drivers. Forensic Sci. Int. 215 (1–3), 14–17.
https://doi.org/10.1016/j.forsciint.2011.01.040.
P., Żaba,
C., 2016. Flubromazolam – A new life-threatening designer benzodiazepine. Clin.
Toxicol. Phila. (Phila) 54 (1), 66–68. https://doi.org/10.3109/15563650.2015.
1112907.
Manchester, K.R., Lomas, E.C., Waters, L., Dempsey, F.C., Maskell, P.D., 2018. The
emergence of new psychoactive substance (NPS) benzodiazepines: a review. Drug
Test. Anal. 10 (2), 392–393. https://doi.org/10.1002/dta.2349.
Maskell, P.D., Paoli, G.D., Seetohul, L.N., Pounder, D.J., 2011. Phenazepam is currently
being misused in the UK. BMJ 343, d4207. https://doi.org/10.1136/bmj.d4207.
Meng, L., Zhu, B., Zheng, K., Fu, S., 2017. Ultrasound-assisted low-density solvent dispersive
liquid-liquid microextraction for the determination of 4 designer benzodiazepines
in urine samples by gas chromatography-triple quadrupole mass spectrometry.
J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 1053, 9–15. https://doi.
org/10.1016/j.jchromb.2017.04.008.
Meyer, M.R., Pettersson Bergstrand, M., Helander, A., Beck, O., 2016. Identification of
main human urinary metabolites of the designer nitrobenzodiazepines clonazolam,
meclonazepam, and nifoxipam by nano-liquid chromatography-high-resolution mass
spectrometry for drug testing purposes. Anal. Bioanal. Chem. 408 (13), 3571–3591.
https://doi.org/10.1007/s00216-016-9439-6.
Ministry of Justice, Canada, 2018. Benzodiazepines and Other Targeted Substances
Regulations. Accessed January 3, 2019. https://laws-lois.justice.gc.ca/PDF/SOR-
2000-217.pdf.
Moosmann, B., Auwäter, V., 2018. Designer benzodiazepines: another class of new psychoactive
substances. Handb. Exp. Pharmacol. https://doi.org/10.1007/164_2018_
154.
Moosmann, B., Huppertz, L.M., Hutter, M., Buchwald, A., Ferlaino, S., Auwärter, V.,
2013. Detection and identification of the designer benzodiazepine flubromazepam
and preliminary data on its metabolism and pharmacokinetics. J. Mass Spectrom. 48
(11), 1150–1159. https://doi.org/10.1002/jms.3279.
Moosmann, B., Bisel, P., Auwärter, V., 2014. Characterization of the designer benzodiazepine
diclazepam and preliminary data on its metabolism and pharmacokinetics.
Drug Test. Anal. 6 (7–8), 757–763. https://doi.org/10.1002/dta.1628.
Moosmann, B., Bisel, P., Franz, F., Huppertz, L.M., Auwärter, V., 2016. Characterization
and in vitro phase I microsomal metabolism of designer benzodiazepines - an update
comprising adinazolam, cloniprazepam, fonazepam, 3-hydroxyphenazepam, metizolam
and nitrazolam. J. Mass Spectrom. 51 (11), 1080–1089. https://doi.org/10.
1002/jms.3840.
Moosmann, B., Bisel, P., Westphal, F., Wilde, M., Kempf, J., Angerer, V., Auwärter, V.,
2018. Characterization and in vitro phase I microsomal metabolism of designer
benzodiazepines - an update comprising flunitrazolam, norflurazepam and 4’-chlorodiazepam
(Ro5-4864). Drug Test. Anal https://doi.org. 10.1002/dta.2561.
Mortelé, O., Vervliet, P., Gys, C., Degreef, M., Cuykx, M., Maudens, K., Covaci, A., van
Nuijs, A.L.N., Lai, F.Y., 2018. In vitro Phase I and Phase II metabolism of the new
designer benzodiazepine cloniprazepam using liquid chromatography coupled to
quadrupole time-of-flight mass spectrometry. J. Pharm. Biomed. Anal. 153, 158–167.
https://doi.org/10.1016/j.jpba.2018.02.032.
Noble, C., Mardal, M., Bjerre Holm, N., Stybe Johansen, S., Linnet, K., 2017. In vitro
studies on flubromazolam metabolism and detection of its metabolites in authentic
forensic samples. Drug Test. Anal. 9 (8), 1182–1191 https://doi.org/ 10.1002/
dta.2146.
O’Connell, C.W., Sadler, C.A., Tolia, V.M., Ly, B.T., Saitman, A.M., Fitzgerald, R.L., 2015.
Overdose of etizolam: the abuse and rise of a benzodiazepine analog. Ann. Emerg.
Med. 65 (4), 465–466. https://doi.org/10.1016/j.annemergmed.2014.12.019.
Papsun, D., Krywanczyk, A., Vose, J.C., Bundock, E.A., Logan, B.K., 2016. Analysis of MT-
45, a novel synthetic opioid, in human whole blood by LC-MS-MS and its identification
in a drug-related death. J. Anal. Toxicol. 40 (4), 313–317. https://doi.org/10.
1093/jat/bkw012.
Partridge, E., Trobbiani, S., Stockham, P., Charlwood, C., Kostakis, C., 2018. A case study
involving U-47700, diclazepam and flubromazepam–application of retrospective
analysis of HRMS data. J. Anal. Toxicol. 42 (9), 655–660. https://doi.org/10.1093/
jat/bky039.
Pettersson Bergstrand, M., Helander, A., Beck, O., 2016. Development and application of
a multi-component LC-MS/MS method for determination of designer benzodiazepines
in urine. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 1035, 104–110. https://
doi.org/10.1016/j.jchromb.2016.08.047.
Pettersson Bergstrand, M., Helander, A., Hansson, T., Beck, O., 2017. Detectability of
designer benzodiazepines in CEDIA, EMIT II Plus, HEIA, and KIMS II
mass spectrometry. Forensic Sci. Int. 274, 55–63. https://doi.org/10.1016/j.forsciint.
2016.10.021.
Xiang, P., Shen, M., Drummer, O.H., 2015. Review: drug concentrations in hair and their
relevance in drug facilitated crimes. J. Forensic Leg. Med. 36, 126–135. https://doi.
org/10.1016/j.jflm.2015.09.009.